<?xml version="1.0" encoding="UTF-8"?>
<p id="Par42">The interaction between theÂ virus SARS-CoV-2 and RAAS has been proposed as a potential factor in the infectivity of patients, causing several concerns about the use of RAAS inhibitors that may be linked to the action of ACE2, possibly responsible for the virulence of the disease. We know that these drugs are among the most commonly prescribed for the treatment of hypertension, diabetes, and heart failure worldwide, clinical conditions that are strongly associated with an increased risk of an unfavorable evolution of COVID-19 [
 <xref ref-type="bibr" rid="CR30">30</xref>].
</p>
